Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

The Trump administration reached voluntary most-favored-nation (MFN) pricing agreements with 17 of the world’s largest drugmakers since late 2025, aligning certain drug prices to those in comparable developed countries and expanding discounted purchasing via TrumpRx. Pfizer is the first mover, offering discounts on 30+ branded medicines, while management also projects an additional $1.5B decline in COVID-related revenue beyond patent-expiration pressure. AbbVie appears better positioned with Skyrizi (~$4.5B first-quarter 2026 sales, +31% YoY) and Rinvoq (~$2.1B first-quarter 2026 revenue, +23% YoY) expected to offset Humira declines, while Bristol Myers faces a larger combined challenge from impending patent expirations and pipeline replacement needs.

Analysis

This is less a sector-wide earnings reset than a dispersion event. The biggest winners are companies with enough pipeline momentum to absorb a low-single-digit gross-to-net haircut without multiple compression; that favors ABBV over the legacy cash-cows. Names with heavier dependence on aging blockbusters or thinner late-stage replacement stories should see the market treat pricing clarity as a convenience tax that exposes underlying growth gaps rather than as the main problem.

Second-order, the deal structure likely shifts bargaining power toward the largest caps and away from smaller single-asset biotechs that lack scale to negotiate or diversify. If direct-to-consumer channels gain traction, the economic benefit will accrue to products with strong brand loyalty and patient support infrastructure, while pure commodity-like chronic therapies face more price transparency and less room to defend list prices. Any promise of tariff relief or U.S. manufacturing incentives is a subtle tailwind for domestic-capex-heavy pharma and CDMOs, but it matters more to 2026–2027 margin mix than to near-term EPS.

The key risk is that this evolves from voluntary optics into broader mandatory referencing once a political template is established. That would turn a manageable margin headwind into a valuation issue for the whole large-cap pharma basket, especially if Medicaid and direct-to-consumer discounts become the precedent for commercial payers. For now, the market’s discounting likely overstates the earnings hit for diversified innovators and understates the structural pressure on companies still funding growth with mature franchises.

The contrarian take is that regulatory certainty is itself a positive multiple catalyst: pharma investors usually pay up for predictability, not just growth. If the agreement scope stays narrow and pipeline execution remains the primary KPI, the right trade is not to short the whole group but to separate credible compounders from ex-growth balance-sheet stories.

Key Decisions for Investors

• Long ABBV / short BMY for 1-3 months: pair the strongest pipeline replacement story against the most obvious revenue-gap story; target relative outperformance if pricing fear fades and the market refocuses on growth durability.
• Use PFE as a tactical avoid or underweight for the next 2-4 quarters: the issue is not the MFN deal itself but the still-unresolved post-COVID earnings reset; reassess only if core non-COVID revenue inflects positively in guidance or quarterly mix.
• If entering a long-only basket, favor large-cap pharma with visible growth offsets over the headline losers; ABBV is the cleanest expression, while BMY should be reserved for a value-trap monitoring list until late-stage replacement metrics improve.
• Set a watch item on any expansion beyond the current voluntary scope: if pricing referencing broadens to commercial plans or non-participants, fade the entire large-cap pharma group and rotate toward tools, services, and CDMOs less exposed to branded-drug net price compression.
• Falsifier for the bullish ABBV relative call: any sign that Skyrizi/Rinvoq growth decelerates meaningfully or that gross-to-net pressure from pricing deals exceeds low-single-digit revenue drag; if that happens, the pair should be unwound.